Treatment and outcomes of older versus younger women with HER2-positive metastatic breast cancer in the real-world national ESME database
| dc.rights.license | open | en_US |
| dc.contributor.author | ANNONAY, Mylene | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | GAUQUELIN, Lisa | |
| dc.contributor.author | GEISS, Romain | |
| dc.contributor.author | UNG, Mony | |
| dc.contributor.author | CRISTOL-DALSTEIN, Laurence | |
| dc.contributor.author | MOURET-REYNIER, Marie Ange | |
| dc.contributor.author | GONCALVES, Anthony | |
| dc.contributor.author | ABADIE-LACOURTOISIE, Sophie | |
| dc.contributor.author | FRANCOIS, Eric | |
| dc.contributor.author | PERRIN, Christophe | |
| dc.contributor.author | LE FEL, Johan | |
| dc.contributor.author | LORGIS, Veronique | |
| dc.contributor.author | SERVENT, Veronique | |
| dc.contributor.author | UWER, Lionel | |
| dc.contributor.author | JOUANNAUD, Christelle | |
| dc.contributor.author | LEHEURTEUR, Marianne | |
| dc.contributor.author | JOLY, Florence | |
| dc.contributor.author | CAMPION, Loic | |
| dc.contributor.author | COURTINARD, Coralie | |
| dc.contributor.author | VILLACROUX, Olivier | |
| dc.contributor.author | PETIT, Thierry | |
| dc.contributor.author | SOUBEYRAN, Pierre | |
| dc.contributor.author | TERRET, Catherine | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | BELLERA, Carine | |
| dc.contributor.author | BRAIN, Etienne | |
| dc.contributor.author | DELALOGE, Suzette | |
| dc.date.accessioned | 2021-12-07T09:43:51Z | |
| dc.date.available | 2021-12-07T09:43:51Z | |
| dc.date.issued | 2021-10-01 | |
| dc.identifier.issn | 1532-3080 (Electronic) 0960-9776 (Linking) | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/124018 | |
| dc.description.abstractEn | BACKGROUND: Treatment and outcomes of patients with HER2-positive (HER2+) metastatic breast cancer (MBC) have dramatically improved over the past 20 years. This work evaluated treatment patterns and outcomes according to age. METHODS: Women who initiated a treatment for HER2+ MBC between 2008 and 2016 in one of the 18 French comprehensive centers part of the ESME program were included. Objectives were the description of first-line treatment patterns, overall survival (OS), first-line progression-free survival (PFS), and prognostic factors among patients aged 70 years or more (70+), or less than 70 (<70). RESULTS: Of 4045 women diagnosed with an HER2+ MBC, 814 (20%) were 70+. Standard first-line treatment (chemotherapy combined with an anti-HER2 therapy) was prescribed in 65% of 70+ versus 89% of <70 patients (p < 0.01). Median OS was 49.2 (95% CI, 47.1-52.4), 35.3 (95% CI, 31.5-37.0) and 54.2 months (95% CI, 50.8-55.7) in the whole population, in patients 70+ and <70, respectively. Corresponding median PFS1 were 12.8 (95% CI, 12.3-13.3), 11.1 (95% CI, 10.0-12.3) and 13.2 months (95% CI, 12.7-13.9), respectively. In 70+ women, initiation of non-standard first-line treatment had an independent detrimental time-varying effect on both OS and PFS (HR on OS at 1 year: chemotherapy without anti-HER2 2.79 [95% CI: 2.05-3.79]; endocrine therapy and/or anti-HER2 1.96 [95% CI: 1.43-2.69]). CONCLUSIONS: In this large retrospective real-life database, older women with HER2+ MBC received standard first-line treatment less frequently than younger ones. This was independently associated with a worse outcome, but confounding factors and usual selection biases cannot be ruled out. | |
| dc.language.iso | EN | en_US |
| dc.rights | Attribution-NonCommercial-NoDerivs 3.0 United States | * |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/us/ | * |
| dc.subject.en | Metastatic breast cancer | |
| dc.subject.en | Overall survival | |
| dc.subject.en | Elderly | |
| dc.subject.en | HER2 | |
| dc.title.en | Treatment and outcomes of older versus younger women with HER2-positive metastatic breast cancer in the real-world national ESME database | |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1016/j.breast.2021.09.011 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 34624756 | en_US |
| bordeaux.journal | Breast | en_US |
| bordeaux.page | 138-146 | en_US |
| bordeaux.volume | 60 | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.institution | INSERM | en_US |
| bordeaux.team | EPICENE_BPH | |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| hal.identifier | hal-03468488 | |
| hal.version | 1 | |
| hal.date.transferred | 2021-12-07T09:43:56Z | |
| hal.export | true | |
| dc.rights.cc | Pas de Licence CC | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Breast&rft.date=2021-10-01&rft.volume=60&rft.spage=138-146&rft.epage=138-146&rft.eissn=1532-3080%20(Electronic)%200960-9776%20(Linking)&rft.issn=1532-3080%20(Electronic)%200960-9776%20(Linking)&rft.au=ANNONAY,%20Mylene&GAUQUELIN,%20Lisa&GEISS,%20Romain&UNG,%20Mony&CRISTOL-DALSTEIN,%20Laurence&rft.genre=article |
